Oehler Vivian G, Radich Jerald P
Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, D4-100, 1100 Fairview Avenue North, Seattle, WA 98109, USA.
Curr Oncol Rep. 2003 Sep;5(5):426-35. doi: 10.1007/s11912-003-0030-x.
The elucidation of the molecular biology of chronic myeloid leukemia (CML) has provided a paradigm for understanding leukemogenesis, targeted drug development, and disease monitoring at the molecular level. Minimal residual disease (MRD) monitoring by fluorescence in situ hybridization and polymerase chain reaction (PCR) has become an important tool in predicting relapse after allogeneic transplant, allowing for early intervention strategies such as donor lymphocyte infusion. MRD monitoring is important for assessment of disease status in patients who obtain a complete cytogenetic remission, and this approach is likely to play an important role in following patients to determine who will relapse on imatinib mesylate therapy. This review focuses primarily on MRD monitoring by PCR.
慢性髓性白血病（CML）分子生物学的阐明为理解白血病发生、靶向药物开发以及分子水平的疾病监测提供了范例。通过荧光原位杂交和聚合酶链反应（PCR）进行微小残留病（MRD）监测已成为预测异基因移植后复发的重要工具，使得诸如供体淋巴细胞输注等早期干预策略成为可能。MRD监测对于评估获得完全细胞遗传学缓解的患者的疾病状态很重要，并且这种方法可能在跟踪患者以确定哪些患者会在甲磺酸伊马替尼治疗中复发方面发挥重要作用。本综述主要关注通过PCR进行的MRD监测。
